Chenodeoxycholic acid

Chenodeoxycholic acid
Product Name Chenodeoxycholic acid
CAS No.: 474-25-9
Catalog No.: CFN90478
Molecular Formula: C24H40O4
Molecular Weight: 392.57 g/mol
Purity: >=98%
Type of Compound: Steroids
Physical Desc.: Cryst.
Targets: IL Receptor | p38MAPK | PKA
Source: From the bile.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Chenodeoxycholic acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism. Chenodeoxycholic acid could reverse obesity in cHF-fed mice, mainly in response to the reduction in food intake.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Front Aging Neurosci.2018, 10:269
  • J Agric Food Chem.2015, 63(44):9869-78
  • J Clin Med.2019, 8(10):E1664
  • Preprints2017, 2017120176
  • Pathogens.2018, 7(3):E62
  • Microbiol. Biotechnol. Lett.2022, 50(2): 193-201.
  • Molecules.2021, 26(9):2765.
  • Life Sci.2022, 311(Pt A):121157.
  • Molecules.2018, 23(7):E1817
  • Journal of Applied Pharmaceutical Science2022, 0(00), pp:001-007
  • Glycoursodeoxycholic acid

    Catalog No: CFN89075
    CAS No: 64480-66-6
    Price: $100/20mg
    Taurocholic acid

    Catalog No: CFN96646
    CAS No: 81-24-3
    Price: Inquiry(manager@chemfaces.com)
    Tauroursodeoxycholic acid

    Catalog No: CFN96645
    CAS No: 14605-22-2
    Price: Inquiry(manager@chemfaces.com)
    Sodium taurochenodeoxycholate

    Catalog No: CFN80241
    CAS No: 6009-98-9
    Price: Inquiry(manager@chemfaces.com)
    Ursodeoxycholic acid

    Catalog No: CFN96464
    CAS No: 128-13-2
    Price: $30/20mg
    Chenodeoxycholic acid

    Catalog No: CFN90478
    CAS No: 474-25-9
    Price: $30/20mg
    Cholic acid

    Catalog No: CFN99796
    CAS No: 81-25-4
    Price: $30/20mg
    Hyocholic acid

    Catalog No: CFN91626
    CAS No: 547-75-1
    Price: Inquiry(manager@chemfaces.com)
    Deoxycholic acid

    Catalog No: CFN99798
    CAS No: 83-44-3
    Price: $30/20mg
    Lithocholic acid

    Catalog No: CFN89170
    CAS No: 434-13-9
    Price: $40/20mg
    J Gastroenterol Hepatol. 2013 May;28(5):823-8.
    Acidic deoxycholic acid and chenodeoxycholic acid induce interleukin-8 production through p38 mitogen-activated protein kinase and protein kinase A in a squamous epithelial model.[Pubmed: 23425072]
    Immune-mediated mucosal inflammation characterized by the production of interleukin (IL)-8 is associated with the development of gastroesophageal reflux disease. The effects of bile acids, which are major components of reflux fluid, on the production of IL-8 and related mechanisms remain unclear. This study aimed to address these questions using an esophageal stratified squamous epithelial model.
    METHODS AND RESULTS:
    Normal human esophageal epithelial cells were seeded on the Transwell inserts and cultured with the air-liquid interface system to establish the model. Bile acids under different pH conditions were added to the apical compartment to examine their effects on IL-8 production and the underlying cellular signaling. Conjugated bile acids under a neutral or acidic condition did not induce IL-8 production, and unconjugated bile acids, deoxycholic acid (DCA), and Chenodeoxycholic acid (CDCA) all significantly induced IL-8 production, dose- and time-dependently, only under weakly acid conditions. Inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase A (PKA) attenuated the production of IL-8 induced by acidic DCA and CDCA. Inhibition of PKA did not block the bile acid-induced p38 MAPK activation.
    CONCLUSIONS:
    Compared with conjugated bile acids, the unconjugated bile acids DCA and CDCA are more likely to induce IL-8 production in vivo, especially under weakly acid conditions. This process involves two independent signaling pathways, p38 MAPK and PKA.
    J Inherit Metab Dis. 2014 Sep;37(5):851-61.
    Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid.[Pubmed: 24658845]
    A child of consanguineous parents of Pakistani origin developed jaundice at 5 weeks and then, at 3 months, irritability, a prolonged prothrombin time, a low albumin, and episodes of hypoglycaemia. Investigation showed an elevated alanine aminotransferase with a normal γ-glutamyl-transpeptidase.
    METHODS AND RESULTS:
    Analysis of urine by electrospray ionisation tandem mass spectrometry (ESI-MS/MS) showed that the major peaks were m/z 480 (taurine-conjugated 3β-hydroxy-5-cholenoic acid) and m/z 453 (sulphated 3β-hydroxy-5-cholenoic acid). Analysis of plasma by gas chromatography-mass spectrometry (GC-MS) showed increased concentrations of 3β-hydroxy-5-cholenoic acid, 3β-hydroxy-5-cholestenoic acid and 27-hydroxycholesterol, indicating oxysterol 7 α-hydroxylase deficiency. The patient was homozygous for a mutation (c.1249C>T) in CYP7B1 that alters a highly conserved residue in oxysterol 7 α-hydroxylase (p.R417C) - previously reported in a family with hereditary spastic paraplegia type 5. On treatment with ursodeoxycholic acid (UDCA), his condition was worsening, but on Chenodeoxycholic acid (CDCA), 15 mg/kg/d, he improved rapidly. A biopsy (after 2 weeks on CDCA), showed a giant cell hepatitis, an evolving micronodular cirrhosis, and steatosis. The improvement in liver function on CDCA was associated with a drop in the plasma concentrations and urinary excretions of the 3β-hydroxy-Δ5 bile acids which are considered hepatotoxic. At age 5 years (on CDCA, 6 mg/kg/d), he was thriving with normal liver function. Neurological development was normal apart from a tendency to trip. Examination revealed pes cavus but no upper motor neuron signs.
    CONCLUSIONS:
    The findings in this case suggest that CDCA can reduce the activity of cholesterol 27-hydroxylase - the first step in the acidic pathway for bile acid synthesis.
    J Clin Endocrinol Metab. 2013 Aug;98(8):3351-8.
    Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans.[Pubmed: 23783097]
    We hypothesized that intraduodenal infusions of Chenodeoxycholic acid (CDCA) would stimulate FGF and gut peptide secretion, thereby positively influencing glucose homeostasis.
    METHODS AND RESULTS:
    This randomized, double-blind, placebo-controlled, crossover trial included 12 healthy volunteers who received intraduodenal infusions (2.0 mL/min for 180 minutes) of saline, Chenodeoxycholic acid (5 or 15 mmol/L), and a fatty acid (sodium oleate), either alone or with 5 mmol/L Chenodeoxycholic acid. After 60 minutes, an oral glucose tolerance test (oGTT) was performed. Within the first 60 minutes, high-concentration Chenodeoxycholic acid induced a small but significant increase in GLP-1 and CCK secretion (P = .016 and P =.011), whereas plasma C-peptide, insulin, and glucose were not affected. Attenuated C-peptide and insulin release was observed after the oGTT with 15 mmol/L CDCA (P = .013 and P =.011). Plasma BA and FGF19 levels significantly increased after Chenodeoxycholic acid administration (P = .001 and P < .001).
    CONCLUSIONS:
    Chenodeoxycholic acid modulates GLP-1 and CCK secretion; the effect is small and does not influence glucose levels. The marked increase in plasma BAs and the attenuated insulin release after the oGTT indicate the role of BAs in glycemic control, independent of the incretin axis, and suggest involvement of farnesoid X receptor activation pathways.
    Int J Obes (Lond). 2014 Aug;38(8):1027-34.
    Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice.[Pubmed: 24310401 ]
    In this study, the effects of another natural BA, Chenodeoxycholic acid (CDCA), on dietary obesity, UCP1 in both interscapular BAT and in white adipose tissue (brite cells in WAT), were characterized in dietary-obese mice.
    METHODS AND RESULTS:
    Mice were then fed either (i) for 8 weeks with cHF or with cHF with two different doses (0.5%, 1%; wt wt(-1)) of Chenodeoxycholic acid (8-week reversion). In the 8-week reversion, the Chenodeoxycholic acid intervention resulted in a dose-dependent reduction of obesity, dyslipidaemia and glucose intolerance, which could be largely explained by a transient decrease in food intake. The 3-week reversion revealed mild Chenodeoxycholic acid-dependent and food intake-independent induction of UCP1-mediated thermogenesis in interscapular BAT, negligible increase of UCP1 in subcutaneous WAT and a shift from carbohydrate to lipid oxidation.
    CONCLUSIONS:
    Chenodeoxycholic acid could reverse obesity in cHF-fed mice, mainly in response to the reduction in food intake, an effect probably occuring but neglected in previous studies using cholic acid. Nevertheless, Chenodeoxycholic acid-dependent and food intake-independent induction of UCP1 in BAT (but not in WAT) could contribute to the reduction in adiposity and to the stabilization of the lean phenotype.
    3'-Hydroxymirificin

    Catalog No: CFN95102
    CAS No: 168035-02-7
    Price: $338/5mg
    New Compound 1

    Catalog No: CFN95152
    CAS No: N/A
    Price: $398/5mg
    Lanceolarin

    Catalog No: CFN95166
    CAS No: 15914-68-8
    Price: $318/5mg
    1,2-Epoxy-10(14)-furanogermacren-6-one

    Catalog No: CFN95214
    CAS No: 383368-24-9
    Price: $318/10mg
    Chamigrenol

    Catalog No: CFN95247
    CAS No: 19822-80-1
    Price: $318/10mg
    Parishin G

    Catalog No: CFN95324
    CAS No: 952283-93-1
    Price: $318/10mg
    3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester

    Catalog No: CFN95461
    CAS No: 434942-42-4
    Price: $318/5mg
    Methyl ganoderenate B

    Catalog No: CFN95534
    CAS No: N/A
    Price: $413/5mg
    Protocatechuic acid 4-O-beta-glucoside

    Catalog No: CFN95557
    CAS No: 7361-59-3
    Price: $413/5mg
    1-O-Feruloylglucose

    Catalog No: CFN95596
    CAS No: 64625-37-2
    Price: $413/5mg